

Name Faiez Zannad
Title (academic or hospital) MD, PhD Professor
Institutional Affiliation Centre Hospitalier Universitaire
Address Département de Cardiologie
CIC-INSERM-CHU
Hôpital Jeanne d'Arc
BP 90303
F-54201 TOUL
Telephone + 33 3 83 65 66 25
Fax + 33 3 83 65 66 19
CNOM registration number : 2825

I. Personal Information

Name	Faiez (First name)	M. (Middle name/initial)	ZANNAD (Last name)
-------------	-----------------------	-----------------------------	-----------------------

Preferred Mailing Address

<input checked="" type="checkbox"/> Office	CIC-INSERM-CHU Hôpital Jeanne d'Arc BP 90303 54201 TOUL FRANCE
<input type="checkbox"/> Home	

Telephone	+ 33 3 83 65 66 25
Fax	+ 33 3 83 65 66 19
E-mail	cic@chu-nancy.fr

Date of Birth	07/23/1951
----------------------	------------

II. Education and Training

Medical School	Faculté de médecine Nancy - France 1979
-----------------------	---

Specialities	1-	Cardiology and Internal Medicine University Hospital, Nancy, France 1975-1979
	2-	Clinical Pharmacology University of Lyon, France 1981-1984
	3-	Clinical Pharmacology University of Oxford MRC, Oxford UK 1980-1981

Licence to Practice Medicine	1-	Nancy France
	2-	1979

- Fellowships**
- 1- Cardiology
University Hospital, Nancy, France
1981-1986
 - 2- Clinical Pharmacology
University Hospital, Nancy, France
1981-1986
 - 3- Clinical Pharmacology
MRC, Oxford, UK
1980-1981
- Other Related Degrees (e.g., Ph.D.)** PhD Human Biology

Research/clinical program

- Clinical pharmacology of various anti-hypertensive agent
- Clinical trials
- Heart failure
- Hypertension
- Atherosclerosis

Medical Staff/ Hospital

Interne des hôpitaux. Cardiology Internal Medicine
CHU, Nancy - France
1975 - 1980

Assistant des hôpitaux - Cardiology
CHU, Nancy - France
1981-1985

Praticien des hôpitaux - Cardiology
CHU, Nancy - France
1985 - ongoing

Head of Centre de dépistage et de documentation cardiovasculaire and of Centre d'Investigation Clinique (CIC-INSERM-CHU de Nancy, France)
CHU, Nancy - France
1996 - ongoing

Academic Assistant Universitaire, Pharmacology
Faculté de Médecine, Nancy - France
1981-1985

Mâître de Conférence of Pharmacology
Faculté de Médecine, Nancy - France
1985 - 1999

Professor of Therapeutics
Faculté de Médecine, Nancy - France
1999 - ongoing

III. Memberships in Medical/Scientific Societies (National/International)

ISH/ESH

Fellow European Society of Cardiology

- British Pharmacology Society
- International Society of Cardiovascular Pharmacology
- Société Française d'Hypertension
- Société Française de Cardiologie

IV. Other Professional Activities

- Editorial in chief: Fundamental Clinical Pharmacology
- Editorial board of medical journal

List of journals:

- **Journal of Hypertension**
- **Journal of Cardiovascular Pharmacology**
- **Co-Editor of Fundamental and Clinical Pharmacology**
- **Editor of Cardioscopies (France)**

- Referee for medical journal

List of journals :

- Circulation
- American Journal of Hypertension
- Journal of Hypertension
- European Heart Journal
- American Heart Journal
- Journal of Cardiovascular Pharmacology
- American Journal of Kidney Disease
- Drugs etc...

- Other

- Chairman and organizer of annual international meetings : from 1997 to 2002 : "Advanced Drug Research Cardiology" and "Global Cardiovascular Clinical Trialists CVCT Forum" since 2004
- Annual international workshop : Cardiovascular Clinical Trialist Workshop
- Vice chairman of Program Committee ESH Paris 2004 meeting

Honors and Special Recognition

- Officer Board French Society of Hypertension
- Officer Board French Society of Pharmacology

V. Publication/Presentations at Scientific Meetings

Publications

1999

- 99-1. ZANNAD F, BERNAUD C, FAY R, for the general physicians investigators group. Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24-h therapeutic coverage and beyond in patients with mild to moderate hypertension. *J Hypertension*, 1999;17:137-146
- 99-2. ZANNAD F. Nisoldipine Coat-Core and heart rate response during treatment of hypertension. *Int J Clin Pract* 1999;53(1) :65-71
- 99-3. O'CONNOR C, GATTIS WA, McNULTY SE, GHEORGHIAD E M, ADAMS K, CALIFF RM, McKENNA WJ, ZANNAD F, SOLER-SOLER J, SWEDBERG K. Beta-blocker therapy in advanced heart failure : clinical characteristics and long-term outcomes. *Eur J Heart Failure* 1999;1:81-88
- 99-4. ZANNAD F, BRIANÇON S, JUILLIERE Y, MERTES PM, VILLEMOT JP, ALLA F, VIRION JM and the EPICAL investigators. Incidence, clinical and etiologic features, outcomes and prognostic predictors of advanced chronic heart failure. The EPICAL study. *JACC*, 1999;33:734-42
- 99-5. MARIE PY, DANCHIN N, BRANLY F, ANGIOI M, GRENTZINGER A, VIRION JM, BROUANT B, OLIVIER P, KARCHER G, JUILLIERE Y, ZANNAD F, BERTRAND A. Effect of medical therapy on outcome assessment using exercise thallium-201 single photon emission computed tomography imaging. Evidence of a protective effect of beta-blocking antianginal medications. *JACC* 1999;34:113-121
- 99-6. ZANNAD F, BOIVIN JM for the Lorraine General Physician Investigators Group. Ambulatory 24-hour blood pressure assessment of the felodipine-metoprolol combination vs amlodipine in mild to moderate hypertension. *J Hypertens* 1999;17:1023-32
- 99-7. FLUCKIGER L, BOIVIN JM, QUILLIOT D, JEANDEL C, ZANNAD F. Differential effects of aging on heart rate variability and blood pressure variability. *J Gerontol*, 1999;54A:B219-B224
- 99-8. PITT B, ZANNAD F, REMME WJ, CODY R, CASTAIGNE A, PEREZ A, PALENSKY J, WITTES J for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;341:709-17
- 99-9. O'CONNOR CM, GATTIS WA, URETSKY BF, ADAMS KF Jr, McNULTY SE, GROSSMAN SH, McKENNA WJ, ZANNAD F, SWEDBERG K, GHEORGHIAD E M, CALIFF RM. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). *Am Heart J* 1999;138:78-86
- 99-10. STOLTZ JF, ZANNAD F, KHDER Y, LE BRAY DES BOSCS B, GHAWI RE, MEILHAC B, CAUCHOIS G, GENTILS M, MULLER S. Influence of a calcium antagonist on blood rheology and arterial compliance hypertension : comparison with a thiazide diuretic. *Clin Hemorheol Microcirc* 1999;21:201-8
- 99-11. ANAND IS, FRANCIS G, MASERI A, MILAZZOTTO F, PEPINE CJ, YUSUF S, et al. Study on propionyl-L-carnitine in chronic heart failure. *European Heart Journal* 1999;20(1):70-76

2000

- 00-01 ZANNAD F. The potential advantages of a modern antihypertensive therapy in the elderly. *J Cardiovasc Pharmacol* 2000;35:S19-S23
- 00-02 ECEMANN M, ZANNAD F, BRIANCON S, JUILLIERE Y, MERTES PM, VIRION JM, VILLEMOT JP and the EPICAL investigators. Determinants of angiotensin converting enzyme inhibitor prescription in

- severe heart failure with left ventricular systolic dysfunction : the EPICAL study. *Am Heart J* 2000;139:624-31
- 00-03 ALLA F, BRIANCON S, JUILLIERE Y, MERTES PM, VILLEMOT JP, ZANNAD F for the EPICAL Investigators. Differential clinical prognostic classifications in dilated and ischemic advanced heart failure : the EPICAL study. *Am Heart J* 2000;139:895-904
- 00-04 SASS C, PALLAUD C, ZANNAD F, VISVIKIS S. Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas Cohort. *Hum Genet* 2000;107:58-61
- 00-05 SIAGHY EM, DEVAUX Y, SCHROEDER H, SFASKI N, UNGUREANU LONGROIS D, ZANNAD F, VILLEMOT JP, NABET P, MERTES PM. High performance liquid chromatographic analysis of muscular interstitial arginine and norepinephrine kinetics. A microdialysis study in rats. *J of Chromatography B* 2000;745:279-86
- 00-06 DEVAUX Y, GROSJEAN S, SEGUIN C, DAVID C, DOUSSET B, ZANNAD F, MEISTELMAN C, DE TALANCE N, MERTES PM, UNGUREANU-LONGROIS D. Retinoic acid and host pathogen interactions : effects on the inducible nitric oxide synthase in vivo. *Am J Physiol* 2000, 279:E1045-53
- 00-07 ZANNAD F. Effets des inhibiteurs calciques sur la progression de l'athérosclérose et de l'épaisseur intima média. *Drugs*, 2000;59:39-46
- 00-08 ZANNAD F, ALLA F, DOUSSET B, PEREZ A, PITT B on behalf of the RALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES). *Circulation* 2000;102:2700-6
- 00-09 ZANNAD F. Preserving target-organ function with candesartan cilexetil in patients with hypertension. *Blood Pressure* 2000;1:36-9
- 00-010 GOSSE P, SHERIDAN DJ, ZANNAD F, DUBOURG O, GUERET P, KARPOV Y, DE LEEUW PW, PALMA-GAMIZ JL, PESSINA A, MOTZ W, DEGAUTE JP, CHASTANG C, on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. *J Hypertens* 2000;18:1465-75
- 00-011 VISVIKIS S, SASS C, PALLAUD C, GROW MA, ZANNAD F, SIEST G, ERLICH HA, CHENG S. Familial studies in genetics of cardiovascular diseases : the Stanislas cohort. *Clin Chem Lab Med* 2000;38:827-32
- 00-012 SIAGHY EM, DEVAUX Y, SFAKSI N, CARTEAUX JP, UNGUREANU-LONGROIS D, ZANNAD F, VILLEMOT JP, BURLET C, MERTES PM. Consequences of inspired oxygen fraction manipulation on myocardial oxygen pressure, adenosine and lactate concentrations. A combined myocardial microdialysis and sensitive oxygen electrode study in pigs. *J Moll Cell Cardiol* 2000;32:493-504
- 00-013 SEGUIN C, DEVAUX Y, AUBERT N, SIAGHY EM, ZANNAD F, BURLET C, LONGROIS D, MERTES PM. Consequences of labetalol administration on myocardial beta-adrenergic receptors in the brain dead pig. *Annals of Transplantation*, 2000; 5:54-60
- 00-014 ZANNAD F. Anti-aldosterone: the evidence of the RALES study. *Arch Mal Cœur Vaiss* 2000;15 (N° spec.):8-9

2001

- 01-01 PALLAUD C, SASS C, ZANNAD F, SIEST G, VISVIKIS S. Apo CIII, CETP, fibrinogen and MTHFR are genetic determinants of carotid intima media thickness in supposed healthy men (the Stanislas cohort). *Clin Genet* 2001, 59:316-24
- 01-02 ZANNAD F. Have we jugulated the epidemic of heart failure ? One swallow does not make for a summer. *Eur Heart J* 2001;22:188-190

- 01-03 FAGNANI F, BUTEAU L, VIRION JM, BRIANCON S, ZANNAD F. Prise en charge et coût de l'insuffisance cardiaque sévère dans l'étude EPICAL en Lorraine. *Thérapie* 2001;56:5-10
- 01-04 PITT B, WILLIAMS G, REMME W, MARTINEZ F, LOPEZ-SENDON J, ZANNAD F, NEATON J, RONIKER B, HURLEY S, BURNS D, BITTMAN R, KLEIMAN J. The EPHESUS Trial : Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. *Cardiovascular Drugs and Therapy* 2001;15:79-87
- 01-05 GROSJEAN S, DEVAUX Y, SEGUIN C, MEISTELMAN C, ZANNAD F, MERTES PM, KELLY RA, UNGUREANU-LONGROIS D. Retinoic acid attenuates inducible nitric oxide synthase (NOS2) activation in cultured rat cardiac myocytes and microvascular endothelial cells. *J Mol Cell Cardiol* 2001;33:933-45
- 01-06 ZANNAD F, ECHEMANN M, BRIANCON S, JUILLIERE Y, MERTES PM, VILLEMOT JP, ALLA F, VIRION JM for the EPICAL investigators. Outcomes in advanced chronic heart failure. *Cardiology Review* 2001;18:40-43
- 01-07 SHAH MR, STINNETT SS, McNULTY SE, GHEORGHIADE M, ZANNAD F, URETSKY B, ADAMS KF Jr, CALIFF RM, O'CONNOR CM. Hemodynamics as surrogate endpoints for survival in advanced heart failure : an analysis from FIRST. *Am Heart J* 2001, 141:908-14
- 01-08 ZANNAD F, PLETAN Y et les participants de la Table Ronde n° 2 – Rencontres Nationales de Pharmacologie Clinique, Giens Septembre 2000. Difficultés à la réalisation des essais cliniques en France. *Thérapie* 2001;56:341-347
- 01-09 ZANNAD F, SASS C, VISVIKIS S. Environmental and genetic determinants of intima media thickness of the carotid artery. *Clin Exp Pharmacol Physiol* 2001;28:1007-1010
- 01-010 SEGUIN C, DEVAUX Y, GROSJEAN S, SIAGHY EM, MAIROSE P, ZANNAD F, DE TALANCE N, UNGUREANU-LONGROIS D, MERTES PM. Evidence of functional myocardial ischemia associated with myocardial dysfunction in brain-dead pigs. *Circulation* 2001;104-12(suppl) :I197-I201
- 01-011 DEVAUX Y, SEGUIN C, GROSJEAN S, DE TALANCE N, CAMAETI V, BURLET A, ZANNAD F, MEISTELMAN C, MERTES PM, LONGROIS D. Lipopolysaccharide-induced increase of prostaglandin E2 is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane associated prostaglandin E synthase. *J Immunol* 2001;167:3962-3971
- 01-012 ZANNAD F, DOUSSET B, ALLA F. Treatment of congestive heart failure. Interfering the aldosterone-cardiac extracellular matrix relationship. *Hypertension* 2001;38:1227-1232
- 01-013 SASS C, PALLAUD C, ZANNAD F, VISVIKIS S. Association entre le polymorphisme Leu554Phe de la E-sélectine et la pression artérielle au sein de la cohorte Stanislas. *Arch Mal Cœur Vaiss* 2001;94:855-858
- 01-014 PALLAUD C, SASS C, ZANNAD F, SIEST G, VISVIKIS S. L'apo C3, la CETP, le beta-fibrinogène et la MTHFR sont des déterminants génétiques de l'épaisseur intima media de la carotide (cohorte Stanislas). *Arch Mal Coeur Vaiss* 2001;94:851-854
- 01-015 QUILLIOT D, FLUCKIGER L, ZANNAD F, DROUIN P, ZIEGLER O. Impaired autonomic control of heart rate and blood pressure in obesity : role of age and of insulin resistance. *Clin Auton Res* 2001;11:79-86
- 01-016 DEVAUX Y, SEGUIN S, GROSJEAN S, DE TALANCE N, SCHWARTZ M, BURLET A, ZANNAD F, MEISTELMAN C, MERTES PM, UNGUREANU-LONGROIS D. Retinoic acid and lipopolysaccharide act synergistically to increase prostanoid concentrations in rats in vivo. *J Nutr* 2001;131:2628-2635
- 01-017 GUERCI B, KEARNEY SCHWARTZ A, BÖHME P, ZANNAD F, DROUIN P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. *Diabetes Metab* 2001;27:425-434

- 01-018 GUERCI B, BÖHME P, KEARNEY SCHWARTZ A, ZANNAD F, DROUIN P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. *Diabetes Metab* 2001;27:436-447
- 01-019 LEFRANDT JD, HEITMAN J, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, URBIGKEIT A, ROSTRUP M, AGABITI-ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, VAN ROON AM, SMIT AJ. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. *Am J Hypertens* 2001;14:1083-1089
- 01-020 CIBIS II Investigators and Health Economics Group. Reduced costs with bisoprolol treatment for heart failure. An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS II). *Eur Heart J* 2001;22:1021-1031
- 01-021 ERDMANN E, LECHAT P, VERKENNE P, WIEMANN H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high risk patient groups with chronic heart failure. *Eur J Heart Failure* 2001;3:469-79
- 01-022 LEFRANDT JD, HEITMANN J, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, URBIGKEIT A, ROSTRUP M, AGABITI-ROSEI E, RAHN KH et al. Constrating effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. *Br J Clin Pharmacol* 2001;52:687-692
- 01-023 The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001; 357:1385-90
- 01-024 BACQUET P, LEVY E, MCGUIRE A, MCMURRAY J, MEROT JL, PASCHEN B, et al. Reduced costs with bisoprolol treatment for heart failure - An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). *European Heart Journal* 2001;22(12):1021-1031
- 01-025 FARSANG C, KAWECKA-JASZCZ K, LANGAN J, MARITZ F, ZANNAD F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. *Clinical Drug Investigation* 2001;21(1):17-23

2002

- 02-01 BREITHARDT G, ZANNAD F, ADRAGAO P. Foreword. *Eur Heart J* 2002, 4, *suppD*, D1-D2
- 02-02 ZANNAD F. Evidence-based drug therapy for chronic heart failure. *Eur Heart J* 2002, 4, *supp D*, D66-D72
- 02-03 ZANNAD F. Case study: optimization of therapy in chronic heart failure. *Eur Heart J* 2002, 4, *supp D*, D131
- 02-04 ALLA F, BRIANCON S, GUILLEMIN F, JUILLIERE Y, MERTES PM, VILLEMOT JP, ZANNAD F, for the EPICAL study. Self-rating of quality of life provides additional prognostic information in heart failure. Insights into the EPICAL study. *Eur J Heart Failure* 4 (2002) 337-343.
- 02-05 ZANNAD F, GILLE B, GRENTZINGER A, BRUNTZ JF, HAMMADI M, BOIVIN JM, HANOTIN C, IGAU B and DROUIN P. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. *Am Heart J*, 2002 *Sept* ;144(3) :508-515
- 02-06 SEGUIN-DEVAUX C, DEVAUX Y, LATGER-CANNARD V, GROSJEAN S, ROCHETTE-EGLY C, ZANNAD F, MEISTELMAN C, MERTES PM, LONGROIS D. Enhancement of the inducible NO synthase activation by retonic acid is mimicked by RAR α agonist in vivo. *Am J Physiol Endocrinol Metab* (2002) 283: E525-E535
- 02-07 THILLY N, BRIANÇON S, JUILLÈRE Y, DUFAY E, ZANNAD F. Angiotensin-converting enzyme inhibitors in congestive heart failure: practice versus guidelines. *J Pharm Technol* 2002;18:229-240

- 02-08 ZANNAD F, KESSLER M, GRUNFELD JP, THUILLIEZ CH. Fosidial: a randomised placebo controlled trial of the effects of Fosinopril on cardiovascular morbidity in haemodialysis patients. Study design and patients' baseline characteristics. *Fund Clin Pharmacol* 2002, 16:353-360
- 02-09 RADAUCEANU A, VIRION JM, BOIVIN JM, ZANNAD F and the CIC General Practitioners Investigators' Group. Time effect profile of antihypertensive agents assessed with trough/peak ratio, smoothness index and dose omission: an ambulatory blood pressure monitoring study with trandolapril vs. Quinalpril. *Fund Clin Pharmacol* 2002,16:545-554
- 02-10 ECHEMANN M, ALLA F, BRIANÇON S, JUILLIÈRE Y, VIRION JM, MERTES PM, VILLEMOT JP, ZANNAD F ON BEHALF OF THE EPICAL INVESTIGATORS. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL STUDY). *Eur J Heart Failure* 2002, 4:647-654
- 02-11 NIPPERT M, DE MAISTRE E, RODERMANN M, VANCON AC, AMREIN D, BREMBILLA-PERROT B, LECOMPTE T, ZANNAD F, ALIOT E. Traitement par lépirudine au cours d'une thrombopénie à l'héparine. *Arch Mal Cœur* 2002, 95 (12):1234-8

2003

- 03-01 PITT B, REMME W, ZANNAD F, NEATON J, MARTINEZ F, RONIKER B, BITTMAN R, HURLEY S, KLEIMAN J, GATLIN M, for the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study Investigators. A Clinical Trial of Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *New England Journal of Medicine* 2003, 348:1309-21
- 03-02 ZANNAD F, BENETOS A. Genetics of Intima Media Thickness. *Current Opinion in Lipidology* 2003,14:191-200
- 03-03 ZANNAD F, RADAUCEANU A, PARATI G. Trough-to-peak ratio, smoothness index and morning-to-evening ratio: why, which and when? *J Hypertens* 2003,21(5):851-4
- 03-04 PLETAN Y, ZANNAD F, JAILLON P et les participants de la Table Ronde N°1 Giens XVIII. Information du public sur les essais cliniques et la recherche. *Thérapie* 2003,58(3):185-196
- 03-05 PLETAN Y, ZANNAD F, JAILLON P. Public information about clinical trials and research. *Thérapie* 2003;58(3):197-208
- 03-06 MARIE PY, MERCENNIER CH, DANCHIN N, DJABALLAH K, GRENTZINGER A, ZANNAD F, OLIVIER P, DJABALLAH W, KARCHER G, VIRION JM, BERTRAND A. Residual exercise SPECT ischemia on treatment is a main determinant of outcome in patients with coronary artery disease treated medically at long-term with beta-blockers *J Nucl Cardiol* 2003,10(4):361-8
- 03-07 THILLY N, BRIANÇON S, JUILLIÈRE Y, DUFAY E, ZANNAD F. Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. *J Eval Pract* 2003,9(3):373-82
- 03-08 ZANNAD F, NIPPERT M, ALIOT E, SADOUL N. Case study: therapeutic options in a patient with heart failure, ventricular tachycardia and atrial fibrillation. *Eur Heart J* 2003, 5(suppl 1) 1105-1107
- 03-09 PITT B, REICHEK N, WILLENBROCK R, ZANNAD F, PHILLIPS RA, RONIKER B, KLEIMAN J, KLAUSE S, BURNES D, WILLIAMS GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. *Circulation* 2003,108(15): 1831-8
- 03-10 THILLY N, ZANNAD F, DUFAY E, JUILLIÈRE Y, BRIANÇON S. Elaboration de recommandations de pratique clinique: les inhibiteurs de l'enzyme de conversion dans l'insuffisance cardiaque. *Thérapie* 2003,58(4):341-349
- 03-11 ANDREJAK M, ZANNAD F, LAVILLE M, DURU G, MOURAD JJ, WAEBER B. Evaluation of different approaches to the treatment of arterial hypertension: combination treatment with low dose

perindopril/indapamide versus sequential treatment of stepped-dose treatment. *Thérapie* 2003, **58(4):351-2**

03-12 PITT B, REMME W, ZANNAD F, NEATON J, MARTINEZ F, RONIKER B, BITTMAN R, HURLEY S, KLEIMAN J, GATLIN M, for the Eplerenone Post-AMI Heart Failure Efficacy and Survival Study Investigators. A Clinical Trial of Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. *Perfusion* 2003;**16(11):409-419**

03-13 MANCIA G, ROSEI EA, CIFKOVA R, DEBACKER G, ERDINE S, FAGARD R, et al. 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. *Journal of Hypertension* 2003;**21(6):1011-1053**

2004

04-01 MARIE, P, MERTES PM, HASSAN-SEBBAG N, DE TALANCE N, DJABALLAH K, DJABALLAH W, FRIBERG J, OLIVIER P, KARCHER G, ZANNAD F, BERTRAND A. Exercise-Release of cardiac Natriuretic Peptides is Markedly Enhanced when Patients with coronary artery disease are treated Medically by Beta Blockers. *J Am Coll Cardiol* 2004;**43(3) :353-359**

04-02 SIMON T, BOUTOUYRIE P, GOMPEL A, CHRISTIN-MAITRE S, LAURENT S, THUILLEZ C, ZANNAD F, BERNAUD C, JAILLON P; The CASHMERE investigators. Rationale, design and methods of the CASHMERE study. *Fundam Clin Pharmacol* 2004;**18(1):131-138**

04-03 MANN DL, MCMURRAY JJ, PACKER M, SWEDBERG K, BORER JS, COLUCCI WS, DJIAN J, DREXLER H, FELDMAN A, KOBER L, KRUM H, LIU P, NIEMINEN M, TAVAZZI L, VAN VELDHUISEN DJ, WALDENSTROM A, WARREN M, WESTHEIM A, ZANNAD F, FLEMING T. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004;**109:1594-1602**

04-04 AYALEW A, MASKALI F, AUDONNET S, MARIE PY, MENU P, MERTES PM, OLIVIER P, FRANCK P, ZANNAD F, KARCHER G, BERTRAND A. Low-flow ischaemia has no deleterious effect on the steady-state kinetics of 201Tl and 99mTc sestamibi within myocardial tissue. *Nucl Med Commun* 2004;**25(5):475-478**

04-05 REMME W, BOCCANELLI A, CLINE C, COHEN-SOLAL A, DIETZ R, HOBBS R, KEUKELAAR K, SENDON JL, MACARIE C, MCMURRAY J, RAUCH B, RUZYLLLO W, ZANNAD F. Increasing awareness and perception of heart failure in Europe and improving care-rationale and design of the SHAPE study. *Cardiovasc Drugs Ther* 2004;**18(2):153-9**

04-06 ZANNAD F. Efficacité comparée des trois stratégies antihypertensives recommandées en Europe. *Am J Cardiovasc Drugs* 2004, **4(1):13-14**

04-07 A. RADAUCEANU, JM BOIVIN, C. BERNAUD, R. FAY, F. ZANNAD and the CIC General Practitioners Investigators' Group. Duration of action and time-effect profile of amlodipine and valsartan assessed with various methods of blood pressure measurement in primary care setting. *Fundamental and Clinical Pharmacology* 2004;**18: 483-491**

04-08 M. FOUCHARD, F. ZANNAD and participants in round table n°4. The results of major clinical trials. Critical assessment, the circulation of information and media coverage. *Thérapie* 2004,**59(3) 323-328**

04-09 M. FOUCHARD, F. ZANNAD et les participants de la table ronde n°4 de Giens XIX. Lecture critique, évaluation, valorisation, information sur les résultats des grands essais cliniques. *Thérapie* 2004,**59(3) 317-322**

04-10 MOURAD JJ, WAEBER B, ZANNAD F, LAVILLE M, DURU G, ANDREJAK M on behalf of the investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. *J Hypertens* 2004;**22:1-8**

- 04-11 MORGAN JM, MARCO J, STOCKX L, ZANNAD F. Educational governance for the regulation of industry-sponsored continuing medical education in interventional and device-based therapies. *Heart J* 2004, *in press*
- 04-12 AUPETIT JF, SENAC JP, LATINI R, ZANNAD F. The artery and the myocardium, two post-infarction targets. *Presse Med* 2004,33(16):1135-6
- 04-13 TOUBOUL PJ, HENNERICI MG, MEAIRS S, ADAMS H, AMARENCO P, DESVARIEUX M, EBRAHIM S, FATAR M, HERNANDEZ HERNANDEZ R, KOWATNOR S, PRATI P, RUNDEK T, TAYLOR A, BORNSTEIN N, CSIBA L, VICAUT E, WOO KS, ZANNAD F. Mannheim Intima-Media Thickness Consensus. On behalf of the Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference, Mannheim, Germany, May 14, 2004. *Cerebrovasc Dis*. 2004,18(4):346-49
- 04-14 SHAF R; DARNE B, ATAR D, ABADIE E, ADAMS KF, ZANNAD F; on behalf of the participants in the 5th Cardiovascular Clinical Trialists Workshopdagger. Pharmacogenomics in cardiovascular clinical trials. *Fundam Clin Pharmacol* 2004,18(6):705-8
- 04-15 MASKALI F, POUSSIER S, MARIE PY, TRAN N, ANTUNES L, OLIVIER P, PLENAT F, MAITREJEAN S, ZANNAD F, KARCHER G. High-resolution simultaneous imaging of SPECT, PET and MRI tracers on histological sections of myocardial infarction. *Journal of Nuclear Cardiology* 2005;12(2):229-30
- 04-16 THUILLEZ C, ZANNAD F. L'essentiel de 2003 dans l'hypertension artérielle. *Arch Mal Cœur Vaiss* 2004,97(1) :39-40

2005

- 05-01 ZANETTI L, ESSEVAZ-ROULET M, LEFEVRE N, RADAUCEANU A, FAY R. Evaluation de la performance d'un outil d'assurance qualité des protocoles institutionnels. *Thérapie* 2005, 60(6):527-37
- 05-02 DUCKI C, ROSE A, RADAUCEANU A, ZANNAD F. Proposition d'un Outil de transmission au patient des Résultats Globaux de la Recherche Biomédicale. Transmission des Résultats Globaux. *Thérapie* 2005, 60(6):545-51
- 05-03 ZANNAD F. Acute heart failure syndromes: the « Cinderella » of heart failure research. *Eur Heart J* 2005, 7(suppl B):B8-B12
- 05-04 GHEORGHIAD E M, ZANNAD F. Modern management of acute heart failure syndromes. *Eur Heart J* 2005, 7(suppl B):B3-B7
- 05-05 MASKALI F, POUSSIER S, MARIE PY, TRAN N, ANTUNES L, OLIVIER P, PLENAT F, MAITREJEAN S, ZANNAD F, KARCHER G. High-resolution simultaneous imaging of SPECT, PET, and MRI tracers on histologic sections of myocardial infarction. *J Nucl Cardiol* 2005;12:229-30
- 05-06 GHEORGHIAD E M, ORLANDI C, BURNETT Jr JC, DEMETS D, GRINFELD L, MAGGIONI A, SWEDBERG K, UDELSON JE, ZANNAD F, ZIMMER C, KONSTAM MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). *J Card Fail* 2005;11(4):260-9
- 05-07 MORGAN JM, MARCO J, STOCKX L, ZANNAD F. Educational governance for the regulation of industry sponsored continuing medical education in interventional and device based therapies. *Heart* 2005;91:710-2
- 05-08 FELLSTROM B, ZANNAD F, SCHMIEDER R, HOLDAAS H, JARDINE A, ROSE H, WILPSHAAR W on behalf of the AURORA study group. Effect of rosuvastatine on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. *Curr Control Trials Cardiovasc Med*. 2005;6(1) :9

- 05-09 ZANNAD F, RADAUCEANU A. Effect of mineralocorticoid receptor blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. *Heart Failure Reviews* 2005,10:71-8
- 05-10 QUILLOT D, ZANNAD F, ZIEGLER O. Impaired response of cardiac autonomic nervous system to glucose load in severe obesity. *Metabolism* 2005,54:966-74
- 05-11 DEWACHTER P, JOUAN-HUREAUX V, FRANCK P, MENU P, DE TALANCE N, ZANNAD F, LAXENAIRE MC, LONGROIS D, MERTES PM. Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption. *Anesthesiology* 2005,103(1):40-49
- 05-12 RUILOPE LM, AGABATI-ROSEI E, BAKRIS GL, MANCIA G, POULTER NR, TADDEI S, UNGER T, VOLPE M, WAEBER B, ZANNAD F. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. *Blood Pressure* 2005, 14(4):196-209
- 05-13 PITT B, WHITE H, NICOLAU J, MARTINEZ F, GHEORGHIADE M, ASCHERMANN M, VAN VELDHUISEN DJ, ZANNAD F, KRUM H, MUKHERJEE R, VINCENT J for the EPHEBUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. *JACC* 2005,46(3):425-31
- 05-14 QUILLIOT D, ALLA F, BOHME P, BRUNTZ JF, HAMMADI M, DOUSSET B, ZIEGLER O, ZANNAD F. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. *International Journal of Obesity* 2005, 29:1321-8
- 05-15 REMME WJ, MCMURRAY JJ, RAUCH B, ZANNAD F, KEUKELAAR K, COHEN-SOLAL A, LOPEZ-SENDON J, HOBBS FD, GROBBEE DE, BOCCANELLI A, CLINE C, MACARIE C, DIETZ R, RUZYLO W. Public awareness of heart failure in Europe: first results from SHAPE. *Eur Heart J* 2005,26:2413-21
- 05-16 ZANNAD F. Managing hypertension: a question of STRATHE. *Journal of Human Hypertension* 2005,19:S3-S7
- 05-17 ALLA F, KEARNEY-SCHWARTZ A, RADAUCEANU A, DAS DORES S, DOUSSET B, ZANNAD F. Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. *Eur J Heart Fail* 2006,8:147-53
- 05-18 WHITE HD, AYLWARD PH, HUANG Z, DALBY AJ, WEAVER D, BARVIK S, MARIN-NETO JA, MURIN J, NORDLANDER RO, VAN GILST WH, ZANNAD F, MCMURRAY J, CALIFF RM, PFEFFER MA, FOR THE VALIANT INVESTIGATORS. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction. Results from the valsartan in acute myocardial infarction trial (VALIANT). *Circulation* 2005, 112:3391-9
- 05-19 MASKALI F, AYALEW A, MARIE PY, ANTUNES L, MERTES PM, ZANNAD F, GRAVIER JM, KARCHER G, BERTRAND A. Changes in first-pass interstitial kinetics of DTPA in myocardium submitted to low-flow ischemia. *Invest Radiol* 2005, 40:766-72
- 05-20 GHEORGHIADE M, ZANNAD F, SOPKO G, KLEIN L, PINA IL, KONSTAM MA, MASSIE BM, ROLAND E, TRAGUM S, COLLINS SP, FILIPPATOS G, TAVAZZI L AND FOR THE INTERNATIONAL WORKING GROUP ON ACUTE HEART FAILURE SYNDROMES. Acute heart failure syndromes: current state and framework for future research. *Circulation* 2005, 112:3358-68
- 05-21 SEGUIN-DEVAUX C, HANRIOT D, DAILLOUX M, LATGER-CANNARD V, ZANNAD F, MERTES PM, LONGROIS D, DEVAUX Y. Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression. *Mol Cell Endocrinol* 2005,245:67-76
- 05-22 BENETOS A, GARDNER JP, KIMURA M, LABAT C, NZIETCHUENG R, DOUSSET B, ZANNAD F, LACOLLEY P, AVIV A. Aldosterone and telomere length in white blood cells. *J Gerontol A Biol Sci Med Sci* 2005,60(12):1593-6

- 06-01 ZANNAD F, MEBAZAA A, JUILLIERE Y, COHEN-SOLAL A, GUIZE L, ALLA F, ROUGE P, BLIN P, BARLET MH, PAOLOZZI L, VINCENT C, DESNOS M, SAMII K for the EFICA investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. *Eur J Heart Fail* 2006, 8(7):697-705
- 06-02 HAFFNER SM, RUILOPE L, DAHLOF B, ABADIE E, KUPFER S, ZANNAD F. Metabolic syndrome, new onset diabetes and new endpoints in cardiovascular trials. *J Card Pharmacol* 2006, 47(3):469-475
- 06-03 MASKALI F, FRANKEN PR, POUSSIER S, TRAN N, VANHOVE C, BOUTLEY H, LE GALL H, KARCHER G, ZANNAD F, LACOLLEY P, MARIE PY. Initial Infarct Size Predicts Subsequent Cardiac Remodeling in the Rat Infarct Model: An In Vivo Serial Pinhole Gated SPECT. *Study J Nucl Med.* 2006;47(2):337-344.
- 06-04 PITT B, GHEORGHIAD E M, ZANNAD F, ANDERSON JL, VAN VELDHUISEN DJ, PARKHOMENKO A, CORBALAN R, KLUG EQ, MUKHERJEE R, SOLOMON H, ON BEHALF OF THE EPHEBUS INVESTIGATORS. Evaluation of eplerenone in the subgroup of EPHEBUS patients with baseline left ventricular ejection fraction $\leq 30\%$. *Eur J Heart Fail* 2006,8:295-301
- 06-05 KOBER L, SWEDBERG K, MCMURRAY JJ, PFEFFER MA, VELAZQUEZ EJ, DIAZ R, MAGGIONI AP, MAREEV V, OPOLSKI G, VAN DE WERF F, ZANNAD F, ERTL G, SOLOMON SD, ZELENKOFKSKE S, ROULEAU JL, LEIMBERGER JD, CALIFF RM. Previously known and newly diagnosed atrial fibrillation. A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. *Eur J Heart Fail* 2006, 8(6):591-8
- 06-06 SLEIGHT P, POULEUR H, ZANNAD F. Benefits, challenges, and registerability of the polypill. *Eur Heart J* 2006, 27(14):1651-6
- 06-07 GREENBERG B, ZANNAD F, PITT B. The role of aldosterone blockade in the future of heart failure treatment post-acute myocardial infarction and beyond. *Am J Cardiol* 2006, 97(10A):34F-40F
- 06-08 ZANNAD F, KESSLER M, LEHERT P, GRUNFELD JP, THUILLIEZ C, LEIZEROVICZ A, LECHAT P. Prevention of cardiovascular events in end stage renal disease: results of a randomized trial of Fosinopril and implications for future studies. *Kidney International* 2006, 70(7):1318-24
- 06-09 ZANNAD F, ADAMOPOULOS C, MEBAZAA A, GHEORGHIAD E M. The challenge of acute heart failure. *Heart Failure Review* 2006, 11(2):135-9
- 06-10 ZANNAD F, BOUSQUET P, GOTHERT M. Editorial. *Fundam Clin Pharmacol* 2006,20(4):337
- 06-11 BOIVIN JM, ROUSSEAU S, FAY R, RADAUCEANU A, ZANNAD F. Utilisation de l'automesure tensionnelle par les médecins généralistes français dans la prise en charge des patients hypertendus. Etude MEGAMET (MEdecins Généralistes et Auto-Mesure Tensionnelle). *Arch Mal Cœur Vaiss* 2006,99(7-8) :

- 07-01 MAGGIONI AP, DARNE B, ATAR D, ABADIE E, PITT B, ZANNAD F. FDA and CPMP rulings on subgroup analyses. *Cardiology* 2007;107:97-102
- 07-02 ZANNAD F, HUVELLE E, DICKSTEIN K, VAN VELDHUISEN KJ, STELLBRINK C, KOBER L, CAZEAU S, RITTER P, MAGGIONI AP, FERRARI R, LECHAT P. Left bundle branch block as a risk factor for progression to heart failure. *Eur J Heart Fail* 2007, 9(1):7-14
- 07-03 TOUBOUL PJ, HENNERICI MG, MEAIRS S, ADAMS H, AMARENCO P, BORNSTEIN N, CSIBA L; DESVARIEUX M, EBRAHIM S, FATAR M, HERNANDEZ HERNANDEZ R, JAFF M, KOWNATOR S, PRATI P, RUNDEK T, SITZER M, SCHMINKE U, TARDIF JC, TAYLOR A,

- VICAUT E, WOO KS, ZANNAD F, ZUREIK M. Mannheim Carotid Intima-Media Thickness Consensus (2004-2006). *Cerebrovasc Dis*, 2007, 14;23(1):75-80
- 07-04 RADAUCEANU A, MOULIN F, DJABALLAH W, MARIE PY, ALLA F, DOUSSET B, VIRION JM, CAPIAUMONT J, KARCHER G, ALIOT E, ZANNAD F. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. *Eur J Heart Fail* 2007,9:370-6
- 07-05 TOBE S, KAWECKA-JASZCZ K, ZANNAD F, VETROVEC G, PATNI R, SHI H. Amlodipine added to Quinapril vs Quinapril alone for the treatment of hypertension in diabetes : The Amlodipine in Diabetes (ANDI) Trial. *J Clin Hypertens* 2007,9;2:120-127
- 07-06 ZANNAD F. Aldosterone antagonist therapy in resistant hypertension. *J Hypertens* 2007,25(4):474-50
- 07-07 GHEORGHIADE M, KONSTAM MA, BURNETT JC JR, GRINFELD L, MAGGIONI AP, SWEDBERG K, UDELSON JE, ZANNAD F, COOK T, OUYANG J, ZIMMER C, ORLANDI C. Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials. *JAMA* 2007,297(12):1332-43
- 07-08 KONSTAM MA, GHEORGHIADE M, BURNETT JC JR, GRINFELD L, MAGGIONI AP, SWEDBERG K, UDELSON JE, ZANNAD F, COOK T, OUYANG J, ZIMMER C, ORLANDI C. *Effects of oral Tolvaptan in patients hospitalized for worsening Heart Failure: the EVEREST outcome trial.* *JAMA* 2007, 297(12):1319-31
- 07-09 LEWIS RM, GORDON D, POOLE-WILSON PA, ZANNAD F. Similarities and differences in Design Considerations for Cell Therapy and pharmacologic Clinical Trials, *Cardiology* 2007, *in press*
- 07-10 ZANNAD F, FAY R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. *Fund Clin Pharmacol* 2007,21:181-90
- 07-11 ZANNAD F. Benefits of first-line combination of perindopril and indapamide in clinical practice for patients with hypertension and diabetes. *Am J Hypertens* 2007, 20(7, suppl1): S9-S14
- 07-12 ALLA F, ZANNAD F, FILIPPATOS G. Epidemiology of acute heart failure syndromes. *Heart Fail Rev* 2007, 12(2):91-5
- 07-13 FILIPPATOS G, ZANNAD F. An introduction to acute heart failure syndromes: definition and classification. *Heart Fail Rev.* 2007, 12(2):87-90
- 07-14 AHMED A, ZANNAD F, LOVE TE, TALLAJ J, GHEORGHIADE M, EKUNDAYO OJ, PITT B. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. *Eur Heart J* 2007,28:1334-1343
- 07-15 BLANGY H, SADOUL N, DOUSSET B, RADAUCEANU A, FAY R, ALIOT E, ZANNAD F. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. *Europace* 2007, 9(9):724-9
- 07-16 ADAMOPOULOS C, ZANNAD F, FAY R, MEBAZAA A, COHEN-SOLAL A, GUIZE L, JUILLIÈRE Y, ALLA F. Ejection fraction and blood pressure: equally powerful and interactive predictors of 4-week mortality in severe acute heart failure. *Eur J Heart Fai* 2007, 9(9):935-941
- 07-17 KESSLER M, ZANNAD F, LEHERT P, PIERRE GRUNFELD J, THUILLIEZ C, LEIZOROVICZ A, LECHAT P, FOR THE FOSIDIAL INVESTIGATORS. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the fosinopril in dialysis study. *Nephrol Dial Transplant* 2007,22(12):3573-9
- 07-18 BORER JS, POULEUR H, ABADIE E, FOLLATH F, WITTES J, PFEFFER MA, PITT B, ZANNAD F. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. *Eur Heart J* 2007, 28(15):1904-9

- 07-19 KEARNEY-SCHWARTZ A, VIRION JM, STOLTZ JF, DROUIN P, ZANNAD F. Haemorrhological disturbances in hypertensive type 2 diabetic patients – influence of antihypertensive therapy. *Fund Clin Pharmacol* 2007, 21(4):387-396
- 07-20 RAJAGOPALAN S, ZANNAD F, RADAUCEANU A, GLAZER R, JIA Y, PRESCOTT MF, KARIISA M, PITT B. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. *Am J Cardiol* 2007, 100(2):222-226
- 07-21 SUI X, GHEORGHIAD E M, ZANNAD F, YOUNG JB, AHMED A. A Propensity Matched Study of the Association of Education and Outcomes in Chronic Heart Failure. *Int J Cardiol* 2007, *in press*
- 07-22 STOUGH WG, ZANNAD F, PITT B, GOLDSTEIN S. Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards. *Am Heart J* 2007,154(2):232-8
- 07-23 FELLSTROM B, HOLDAAS H, JARDINE AG, ROSE H, SCHMIEDER R, WILPSHAAR W, ZANNAD F. Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Patients Baseline Data from the AURORA Study. *Kidney Blood Press Res* 2007,30(5):314-322
- 07-24 CONSTANS J, GERMAIN C, GOSSE PH, TAILLARD J, TIEV K, DELEVAUX I, MOUTHON L, SCHMIDT C, GRANEL F, SORIA P, LIFERMANN F, ETIENNE G, BONNET F, ZOULIM K, FARGE-BANCEL D, MARIE I, ALLANORE Y, CABANE J, AMONCHOT A, MACQUIN-MAVIER I, SAVES M, ZANNAD F, CONRI C and the ERAMS investigators. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study? *J Hypertens* 2007,9:1900-1906

2008

- 08-01 MEBAZAA A, GHEORGHIAD E M, PIÑA IL, HARJOLA VP, HOLLENBERG SM, FOLLATH F, RHODES A, PLAISANCE P, ROLAND E, NIEMINEN M, KOMAJDA M, PARKHOMENKO A, MASIP J, ZANNAD F, FILIPPATOS G. Practical Recommendations For Pre-Hospital and Early In-Hospital Management of Patients Presenting with Acute Heart Failure Syndromes. *Crit Care Med.* 2008;36(1 Suppl):S129-39
- 08-02 QUILLIOT D, BÖHME P, ZANNAD F, ZIEGLER O. Sympathetic-leptin relationship in obesity: effect of weight loss. *Metabolism*, *in press*
- 08-03 ZANNAD F, GATTIS STOUGH W, PITT B, CLELAND JGF, ADAMS K, GELLER NL, TORP-PEDERSEN C, KIRWAN BA, FOLLATH F. Heart Failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. *Eur H J* 2008,29:413-21
- 08-04 DE LUCA L, MEBAZAA A, FILIPPATOS G, PARISSIS JT, BOHM M, VOORS AA, NIEMINEN M, ZANNAD F, RHODES A, EL-BANAYOSY A, DICKSTEIN K, GHEORGHIAD E M. Overview of emerging pharmacologic agents for acute heart failure syndromes. *Eur J Heart Fail* 2008,10:201-13
- 08-05 RADAUCEANU A, DUCKI C, VIRION JM, MALLAT Z, MCMURRAY J, VAN VELDHUISEN DJ, TAVAZZI L, MANN DL, CAPIAUMONT-VIN J; LI M; HANRIOT D; ZANNAD F. Extracellular Matrix Turnover and Inflammatory Markers Independently predict Functional Status and Outcome in Chronic Heart Failure. Collagen markers predict functional capacity. *J Card Fail* 2008, *in press*
- 08-06 BELLO G, CAILOTTO F, HANRIOT D, KOLOPP-SARDA MN, LATGER-CANNARD V, HESS K, ZANNAD F, LONGROIS D, ROPARS A. C-reactive protein (CRP) increases VEGF-A expression in monocyte cells via a PI3-kinase and ERK 1/2 signalling dependent pathway. *Atherosclerosis* 2008, *in press*
- 08-07 ZANNAD F, STOUGH WG, PITT B, CLELAND JG, ADAMS KF, GELLER NL, TORP-PEDERSEN C, KIRWAN BA, FOLLATH F. Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. *Eur Heart J* 2008;29(3):413-421

Presentations at Scientific Meetings

1999

BERRICHI H, TIBERGE M, ZANNAD F. Behavioral activities as a predictive parameters in the detection of subtle variations of vigilance in real-life driving situations. *Sleep Research 1999;suppl:54 (abstract 43)*

GOSSE P, DUBOURG O, GUERET P, SHERIDAN DJ, CALVO-GOMEZ C, DEGAUTE JP, KARPOV Y, DE LEEUW P, MOTZ W, PALMA-GAMITZ JL, PESSINA A, ZANNAD F, DE CORDOUE A, BARRANDON S, CHASTANG C, GUEZ D. Regression of left ventricular hypertrophy in patients treated with indapamide SR 1.5 vs enalapil 20 : results of LIVE study. *JACC, February 1999;33:246A*

GROUPE COLLABORATIF DES CIC DE LILLE, NANCY, PARIS-BROUSSAIS, PARIS-ST ANTOINE ET TOULOUSE POUR L'ETUDE ATLAS-NICARDIPINE, ET P. SASSANO, NOVARTIS, FRANCE. 24-hour blood pressure and sympathetic tone after slow-release nicardipine LP 100 mg in essential hypertensive patients : a randomized double-blind parallel study. *Congrès de la Société Française de Pharmacologie, Nantes, 1999*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE DAM PJ, SMIT AJ. Autonomic balance is shifted toward increased vagal predominance during verapamil compared with amlodipine in patients with mild to moderate hypertension. The Vamphyre Study. *Am J Hypertens 1999;12 (suppl 3):29A*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, SMIT AJ. Divergent effects of dihydropyridine and phenylalkylamine calcium antagonist on plasma norepinephrine before and after cold pressor test in mild to moderate hypertension. *Am J Hypertens 1999;12:60A*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, VAN ROON AM, SMIT AJ. Improved short-term blood pressure control by treatment with calcium antagonists in patients with mild to moderate hypertension. *Am J Hypertens 1999;12:130A*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, SMIT AJ. Divergent effects of dihydropyridine and phenylalkylamine calcium antagonist on plasma norepinephrine before and after cold pressor test in mild to moderate hypertension. *J Hypertens 1999;17 (suppl 3):S132*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, VAN ROON AM, SMIT AJ. Improved short-term blood pressure control by treatment with calcium antagonists in patients with mild to moderate hypertension. *J Hypertens 1999;17 (suppl 3):S66*

LEFRANDT JD, URBIGKEIT A, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, HEITMANN J, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, SMIT AJ. Autonomic balance is shifted toward increased vagal predominance during verapamil compared with amlodipine in patients with mild to moderate hypertension. The Vamphyre Study. *J Hypertens 1999;17 (suppl 3):S133*

GOSSE P, SHERIDAN DJ, DUBOURG O, GUERET P, KARPOV Y, DE LEEUW P, PALMA-GAMIZ JL, CALVO-GOMEZ C, PESSINA A, MOTZ W, DEGAUTE JP, CHASTANG C, ZANNAD F. Diuretics versus angiotensin converting enzyme inhibitors in the regression of left ventricular hypertrophy in hypertensive patients : the LIVE study. *J Hypertens 1999;17:S73*

ECEMANN M, ZANNAD F, BRIANCON S, ALLA F, VIRION JM, JUILLIERE Y, VILLEMOT JP. Antithrombotic therapy is associated with better survival in patients with severe heart failure. *Eur Heart J 1999;20:28*

SIAGHY EM, DEVAYX Y, SFAKSI N, HALEJCIO-DELOPHONT P, ZANNAD F, UNFUREANU-LONGROIS D, BURLET C, VILLEMOT JP, MERTES PM. The protective effect of labetalol on myocardial function in brain-dead pids is associated with attenuated increase in myocardial microdialysis concentrations of adenosine and lactate. *Eur Heart J* 1999;20:434

SIAGHY EM, DEVAUX Y, SFAKSI N, UNGUREANU-LONGROIS D, ZANNAD F, VILLEMOT JP, NABET P, BURLET C, SCHROEDER H, MERTES PM. High performance liquid chromatographic analysis of muscular interstitial arginine and norepinephrine dinetics. A microdialysis study in rats. *Arch Mal Cœur Vaiss* 1999;92(4):490

PITT B, ZANNAD F, REMME WJ, CODY RJ. Spironolactone appears beneficial regardless of ejection fraction : the RALES trial. *Circulation* 1999;100:I-298

LEFRANDT JD, HEITMAN J, SEVRE K, CASTELLANO M, HAUSBERG M, MURPHY M, ZANNAD F, et al. Sex differences in autonomic function in patients with mild to moderate hypertension. *Circulation* 1999;100:I-608

QUILLIOT D, FLUCKIGER L, HAMMADI M, VIRION JM, DROUIN P, ZIEGLER O, ZANNAD F. Diminution de la variabilité de la fréquence cardiaque du sujet obèse : rôle de l'âge et de la composition corporelle. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. *Arch Mal Coeur Vaiss* 1999;92:46(P87)

KEARNEY-SCHWARTZ A, VIRION JM, FLUCKIGER L, KHDER Y, STOLTZ JF, DROUIN P, ZANNAD F. La géométrie, la compliance et la distensibilité de l'artère radiale chez les patients hypertendus diabétiques type 2. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. *Arch Mal Coeur Vaiss* 1999;92:31(P2)

KEARNEY-SCHWARTZ A, VIRION JM, FLUCKIER L, KHDER Y, STOLTZ JF, DROUIN P, ZANNAD F. Hyperstimulation endothéliale par augmentation des contraintes de cisaillement pariétales chez les patients hypertendus diabétiques. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. *Arch Mal Coeur Vaiss* 1999;92:31(P3)

ZANNAD F, ZIEGLER O, GILLE B, GRENTZINGER A, BRUNTZ JF, HAMMADI M, FLUCKIGER L, BOIVIN JM, HANOTIN C. Un traitement amaigrissant par Sibutramine n'entraîne pas de modification cliniquement significative des paramètres cardiovasculaires, de la géométrie et de la fonction du ventricule gauche et des valves cardiaques. XIXes Journées de l'hypertension Artérielle, Paris, 9-10 décembre 1999. *Arch Mal Coeur Vaiss* 1999;92:41(P57)

2000

PALLAUD C, SASS C, ZANNAD F, SIEST G, VISVIKIS S. ApoCIII, CETP, fibrinogen, MTHFR and PON are genetic determinants of carotid protid intima media thickness in the Stanislas Cohort. *Arch Mal Cœur Vaiss* 2000;93:129

GOSSE P, SHERIDAN D, ZANNAD F, DUBOURG O, GUERET P, KARPOV Y, de LEEUW P, PALMA-GAMIZ JL, PESSINA A, MOTZ W, DEGAUTE JP, CHASTANG C. Régression de l'hypertrophie ventriculaire gauche chez l'hypertendu traité par indapamide LP 1,5 mg ou énalapril 20 mg : l'étude LIVE. *Arch Mal Cœur Vaiss* 2000;93:16

DEVAUX Y, GROSJEAN S, SEGUIN C, MEISTELMAN C, ZANNAD F, MERTES PM and LONGROIS D. Effect of retinoic acid (RA) on cyclooxygenases (Cox) in LPS-stimulated rats in vivo. *Arch Mal Cœur Vaiss* 2000;93:421

ZANNAD F, ALLA F, DOUSSET B, PITT B ON BEHALF OF THE RALES STEERING COMMITTEE AND INVESTIGATORS. Survival benefits of spironolactone therapy may be explained by the limitation of the excessive extracellular matrix turnover in patients with CHF : insights from the RALES trial. *JACC* 2000;35 (suppl A): 203A

ALLA F, BRIANCON S, JUILLIERE Y, MERTES PM, VILLEMOT JP, GUILLEMIN F, ZANNAD F. Quality of life measures predict mortality and hospitalization in patients with advanced heart failure. Insights from the EPICAL study. *JACC* 2000.35(suppl A):238A

- KEARNEY-SCHWARTZ A, VIRION JM, STOLTZ JF, DROUIN P, ZANNAD F. Endothelial hyperstimulation with increased wall shear stress in hypertensive diabetic type 2 patients. *J Hypertens* 2000;18 (suppl 4):S191
- KEARNEY-SCHWARTZ A, VIRION JM, STOLTZ JF, DROUIN P, ZANNAD F. Geometry, compliance and distensibility of the radial artery in hypertensive patients with type 2 diabetes. *J Hypertens* 2000;18 (suppl 4):S189
- ZANNAD F, ALLA F, ECHEMANN M, FAGNANI F, VIRION JM, JUILLIERE Y, BRIANÇON S. Decreased renal function is a major determinant of outcome, health management and ACE inhibitor therapy prescription and dosage in patients with congestive heart failure. Results from the EPICAL study. *Eur Heart J* 2000;21:537
- ZANNAD F, FAGNANI F, BUTEAU L, VIRION JM, ALLA F, ECHEMANN M, JUILLIERE Y, BRIANÇON S. Factors contributing to health care resource use and to cost related to the management of patients with congestive heart failure : results from the EPICAL study. *Eur Heart J* 2000;21:220
- SASS C, ZANNAD F, PALLAUD C, VISVIKIS S. Apo CIII, CETP, Fibrinogen and MTHFR and genetic determinants of carotid intima media thickness in healthy men (the STANISLAS Cohort). *Eur Heart J* 2000;21:611
- ZANNAD F, ALLA F, DOUSSET B, PEREZ A, PITT B ON BEHALF OF THE RALES STEERING COMMITTEE AND INVESTIGATORS. Mechanisms contributing to the survival benefit with aldosterone antagonist therapy in heart failure : Effects on neurohormones and cardiac fibrosis. substudy of RALES. *Eur Heart J* 2000;21:22
- ZANNAD F, ALLA F, DOUSSET B, PITT B. Limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of spironolactone on survival in patients with CHF : insights from the RALES trial. *Eur J Heart Failure* 2000;2:98
- ZANNAD F, ALLA F, DOUSSET B. Determinants and prognostic value of serum markers of cardiac fibrosis in heart failure : results from the RALES database. *Eur J Heart Failure* 2000;2:104
- LEFRANDT JD, HEITMANN J, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, URBIGKEIT A, ROSTRUP M, AGABITI ROSEI E, RAHN KH, MURPHY M, ZANNAD F, DE KAM PJ, SMIT AJ. Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension. *J Hypertens* 2000;18:S98
- LEFRANDT J, HEITMANN J, SEVRE K, CASTELLANO M, HAUSBERG M, FALLON M, FLUCKIGER L, URBIGKEIT A, ROSTRUP M, AGABITI-ROSEI E, RAHN K, MURPHY M, ZANNAD F, DE DAM P, SMIT A. Effects of verapamil and amlodipine on plasma norepinephrine and cardiovascular load during stress in hypertension. *J Hypertens* 2000;18:S157
- PALLAUD C, SASS C, ZANNAD F, SIEST G, VISVIKIS S. L'apo CIII, la CETP, le fibrinogène et la MTHFR sont des déterminants génétiques de l'épaisseur intima media de la carotide chez des hommes sains (la cohorte Stanislas). *Arch Mal Cœur Vaiss* 2000;93:17
- SASS C, PALLAUD C, ZANNAD F, VISVIKIS S. Association entre le polymorphisme LEU554PHE de la E-selectine et la pression artérielle au sein de la cohorte Stanislas. *Arch Mal Cœur Vaiss* 2000;93:17
- 2001**
-
- ZANNAD F, ALLA F, KEARNEY SCHWARTZ A, DOUSSET B. Sensitivity, specificity and prognostic value of serum markers of cardiac extracellular matrix turnover in heart failure. *J Am Coll Cardiol* 2001;37:166A
- ZANNAD F. Epidémiologie de l'insuffisance cardiaque avancée en Lorraine. *Arch Mal Cœur Vaiss* 2001;94 (suppl.):83
- ZANNAD F. Aldosterone antagonists in the treatment of heart failure. The RALES study. *Arch Mal Cœur Vaiss* 2001;94 (suppl.):36
- ZANNAD F. Le traitement pharmacologique de l'insuffisance cardiaque chronique (ICC). La situation en France. *Arch Mal Cœur Vaiss* 2001;94 (suppl.):113

ZANNAD F. Recent clinical trials in pharmacological treatment of heart failure. *Cardiovascular Drug Therapy* 2001;15:117

ZANNAD F. Cardiac extracellular matrix as a target for pharmacotherapy in congestive heart failure. *Cardiovascular Drug Therapy* 2001;15:12

ZANNAD F. Recent clinical trials in pharmacological treatment of heart failure. *Jpn Circ J* 2001;65 (suppl I-A):49

BÖHME Ph, KEARNEY-SCHWARTZ A, PAUL JL, ZANNAD F, ZIEGLER O, DROUIN P, GUERCI B. Dysfonction endothéliale du sujet coronarien : influence des lipides postprandiaux. *Diabetes & Metabolism* 2001;27 (suppl 1): S65

DEVAUX Y, SEGUIN C, GROSJEAN S, DE TALANCE N, MEISTELMAN C, ZANNAD F, MERTES PM, LONGROIS D. Inducible NO synthase (NOS2) – Cyclooxygenases (COX) cross-talk in vivo : implication for pharmacological inhibition of NOS2 activity. *Arch Mal Cœur Vaiss* 2001;94:354

SASS C, PALLAUD C, ZANNAD F, VISVIKIS S. Association entre le polymorphisme Leu554phe de la E-selectine et de la pression artérielle (cohorte Stanislas). *Arch Mal Cœur Vaiss* 2001;94:390

ZANNAD F, ALLA F, VIRION JM, JUILLIERE Y, BRIANCON S. Long term, 5 year-survival and prognostic factors in patients hospitalized with advanced heart failure, in the EPICAL study. *Eur Heart J*, 2001;22:259

ZANNAD F, ALLA F, DOUSSET B, KEARNEY SCHWARTZ A, LEFEVRE N. Changes of serum markers of cardiac extracellular matrix turnover in heart failure and high risk patients. *Eur Heart J*, 2001;22:378

RADAUCEANU A, VIRION JM, FLUCKIGER L, ZANNAD F. Time effect profile of antihypertensive agents assessed with trough/peak ratio : an ambulatory blood pressure monitoring study with trandolapril vs quinapril. *Fund Clin Pharmacol* 2001;15 (suppl 1):92

ZANNAD F, ZIEGLER O, GILLES B, GRENTZINGER A, BRUNTZ JF, HAMMADI M, BOIVIN JM, HANOTIN C, DROUIN P, the GPs Investigators. Reduction in left ventricular mass with weight loss on sibutramine treatment for obesity. *Fund Clin Pharmacol* 2001;15 (suppl 1):123

BOHME P, KEARNEY-SCHWARTZ A, PAUL JL, ZANNAD F, ZIEGLER O, DROUIN P, GUERCI B. Postprandial lipid metabolism and endothelial dysfunction in men with coronary heart disease. *Diabetes* 2001;50 (suppl2):A450

MERCENIER C, HASSAN N, OLIVIER P, MARIE PY, LAURENS MH, GRENTZINGER A, ZANNAD F, DANCHIN N, KARCHER G, BERTRAND A. Failure to prevent exercise-spet ischemia, in coronary artery disease treated medically by beta-blockers, leads to a delayed but dramatic worsening of outcome. *Eur J Nuclear Med* 2001;28:977

ALLA F, QUILLIOT D, DOUSSET B, ZIEGLER O, BÖHME P, ZANNAD F. L'insulino-résistance est un facteur indépendant de fibrose cardiaque chez l'obèse. *Arch Mal Cœur Vaiss* 2001;95:6

KEARNEY SCHWARTZ A, BERNAUD C, STOLTZ JF, DROUIN P, ZANNAD F. Modifications hémorhéologiques, diamètre et compliance artériels chez des patients hypertendus diabétiques de type 2 : influence du traitement antihypertenseur. *Arch Mal Cœur Vaiss* 2001;95:20

BOHME Ph, KEARNEY-SCHWARTZ A, ZIEGLER O, PAUL JL, ZANNAD F, DROUIN P, GUERCI B. Dysfonction endothéliale et métabolisme lipidique postprandial chez le sujet coronarien: influence des acides gras libres. "Nutrition – Obésité 2001" Congrès commun AFERO, AFN & SNDLF – 29 et 30 novembre 2001.

2002

ZANNAD F, ALLA F, DOUSSET B, KEARNEY-SCHWARTZ A, LEFEVRE N. Changes of serum markers of cardiac extra-cellular matrix turnover in heart failure and high risk patients. *J Hypertens* 2002, 20 (suppl 4), page S2

KEARNEY-SCHWARTZ A, BERNAUD C, STOLTZ JF, DROUIN P, ZANNAD F. Influence of antihypertensive therapy on hemorheological modifications, arterail diameter and compliance in hypertensive type 2 diabetic patients. *J Hypertens* 2002, 20 (suppl 4), page S72

ALLA F, QUILLOT D, DOUSSET B, ZIEGLER O, BOHME Ph, ZANNAD F. Insulin-resistance is an independent determinant of cardiac fibrosis in obesity. *J Hypertens* 2002, 20 (suppl 4), page S59

ZANNAD F, ALLA F, ECHEMANN M, HACQUARD G, RISSE B, KESSLER M. Cardiovascular mortality in chronic haemodialysis patients: CORDIAL, a 3-year follow up cohort study. *Eur Heart J* 2002, 23:107

ZANNAD F, COHEN SOLAL A, DESNOS M, GUIZE LJ, JUILLIÈRE Y, MEBAZZA A, ROUGE P, SAMII K on behalf of the EFICA Investigators. Clinical and etiological features, management and outcomes of acute heart failure: the EFICA cohort study. *Eur Heart J* 2002, 23:579

ALLA F, BRIANÇON S, ZANNAD F. Elaboration and Validation of a Prognostic Classification for Severe Chronic Heart Failure: Data from EPICAL and RALES studies. *JACC* 2002, 39(5):802-1

RADAUCEANU A, BOIVIN JM, BERNAUD C, ZANNAD F. Durée d'action et efficacité résiduelle après omission de dose de l'Amlodipine et du Valsartan dans une population d'hypertendus. *Arch Mal Cœur Vaiss* 2002, 95:P118

BOIVIN JM, RADAUCEANU A, BERNAUD C, ZANNAD F. Effets comparés de l'Amlodipine et du Valsartan sur la pression artérielle résiduelle, chez des patients hypertendus suivis en ambulatoire. *Arch Mal Cœur Vaiss* 2002, 95:P119

GUERCI B, BÖHME PH, KEARNEY-SCHWARTZ A, ZIEGLER O, PAUL JL, ZANNAD F, DROUIN P. Lipides postprandiaux et dysfonction endothéliale du sujet coronarien rôle des acides gras libres. *Annales d'Endocrinologie* 2002, 63(4):283

WILLENBROCK R, PITT B, DARIUS F, ZANNAD F, ALONSO VB, HE W, BURNS D, RONIKER B. Selective aldosterone blockade with eplerenone regresses ventricular mass in patients with left ventricular hypertrophy. *Eur Heart J* 2002, 23(vol 4, Abstr Suppl.):211

ZANNAD F, COHEN SOLAL A, DESNOS M, GUIZE L, JUILLIÈRE Y, MEBAZAA A, ROUGÉ P, SAMII K, the EFICA investigators. Clinical and etiological features, management and outcomes of acute heart failure: the EFICA cohort study. *Eur Heart J* 2002, 23(vol 4, Abstr Suppl.):579

ZANNAD F, ALLA F, ECHEMANN M, HACQUARD G, RISSE B, KESSLER M. Cardiovascular mortality and morbidity in chronic haemodialysis patients: CORDIAL, a 3-year follow-up cohort study. *Eur Heart J* 2002, 23 (vol 4, Abstr Suppl.): 107

ZANNAD F. Aldosterone antagonists for all heart failure patients? *Arch Mal Cœur Vaiss* 2002, 95:47

JUILLIERE Y, ALLA F, ZANNAD F, BRIANCON S. Epidémiologie de l'insuffisance cardiaque sévère. *Arch Mal Cœur Vaiss* 2002, 95:20

2003

PITT B, REMME W, ZANNAD F, NEATON J, GATLIN M, RONIKER B, HURLEY SM, BITTMAN R. EPHEBUS (Eplerenone Post-AMI Heart Failure Efficacy and Survive Study): A double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction. *JACC* 2003

WHITE HD, AYLWARD PE, DALBY A, DOUGLAS W, SWEDBERG K, BARVIK S, MARIN-NETO J, MURIN J, NORLANDER R, VAN GILST WH, ZANNAD F, Green Lane Hospital, Auckland, New Zealand. The effect of age on early death and stroke rates in patients with heart failure after acute myocardial infarction. *JACC* 2003

BOIVIN JM, RADAUCEANU A, BERNAUD C, ZANNAD F, and the CIC General Practitioners Investigator's Group. Comparison of antihypertensive trough effect of amlodipine versus valsartan in hypertensive outpatients. *ESH MILAN Juin 2003 (poster) J Hypertens* 2003

RADAUCEANU A, BOIVIN JM, BERNAUD C, ZANNAD F, and the CIC General Practitioners Investigator's Group. Duration of action and BP lowering after dose omission of amlodipine and valsartan in hypertensive patients. *ESH MILAN Juin 2003 (poster) J Hypertens 2003*

ZANNAD F. Chronic heart failure and activation of sympathetic nervous system and RAAS : progression of detrimental steps. *Eur J Heart Failure Juin 2003*

MOULIN F, RADAUCEANU A, DJEBALLAH W, DOUSSET B, ALLA F, MARIE PY, KARCHER G, ALIOT E, ZANNAD F. Chronic myocardial ischemia is associated with changes in serum markers of cardiac extra-cellular matrix turnover contributing to cardiac fibrosis. *Circulation 2003, 108 (17) :3052*

REMME W, MC MURRAY J, RAUCH B, ZANNAD F, KEUKELAAR K, COHEN-SOLAL A, RUZYLLO W, LOPEZ-SENDON J on behalf of the SHAPE study group. SHAPE (study of heart failure awareness and perception in Europe): a pan-European general public survey on awareness and perception of the clinical, social and economic importance of heart failure. *Eur Heart J 2003,24 (abstract suppl):P1027*

THILLY N, BRIANÇON S, JUILLIÈRE Y, DUFAY E, ZANNAD F. Improving angiotensin-converting enzyme inhibitor use in patients hospitalised with systolic heart failure: a cluster randomised controlled trial. *Eur Heart J 2003,24 (abstract suppl): P1585*

MANHENKE C, ORN S, DICKSTEIN K, AARSLAND F, ZANNAD F. Elevated levels of serum of C-terminal talopeptide of type I collagen (ICTP) are strongly associated with increased mortality in patients following complicated acute myocardial infarction. *Circulation 2003, 108 (17):689*

FELLSTRÖM B, ZANNAD F, SCHMIEDER R, HOLDAAS H, JARDINE A, ARMSTRONG J, SIEWERT-DELLE A on behalf of the AURORA Study Group. A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study. *Nephrology Dialysis and Transplantation 2003; 18 (suppl): Abstract W520*

REMME W, CLINE C, COHEN SOLAL A, HOBBS R, KEUKELAAR K, LOPEZ SENDON J, MACARIE C, MC MURRAY J, RAUCH B, ZANNAD F. SHAPE: A pan-european general public heart failure awareness and perception survey. *Circulation 2003, 108 (17): 3150*

WHITE HD, AYLWARD PE, DALBY A, WEAVER WD, SWEDBERG K, ZANNAD F, MC MURRAY J, PFEFFER MA. One-year mortality, stroke, and myocardial infarction rates remain high in the elderly despite beta-blockade plus angiotensin-converting-enzyme inhibition, angiotensin receptor blockade, or both: the VALIANT trial. *Circulation 2003, 108 (17): 3161*

PITT B, KRUM H, NICOLAU JC, CARDOSO S, PARKHOMENKO A, ASCHERMANN M, ZANNAD F, BITTMAN R, KLEIMAN J. The EPHEBUS trial: Effect of Eplerenone in Patients with a Baseline History of Hypertension. *Circulation 2003, 108 (17): 2727*

2004

WAEBER B, ANDREJACK M, ZANNAD F, LAVILLE M, DURU G, MOURAD JJ. Traitement antihypertenseur: comparaison de trois stratégies thérapeutiques actuellement recommandées. *Arch Mal Cœur Vaiss 2004, 97(2) :S189*

ZANNAD F. Des grands essais aux recommandations: de l'artère obstruée au muscle sauvé. *Arch Mal Cœur Vaiss 2004, 97(2) :C285*

THUILLEZ CH, ZANNAD F. Essais cliniques, recommandations et pratiques quotidiennes dans l'HTA. *Arch Mal Cœur Vaiss 2004, 97(2) :S13*

MANHENKE CA, STEIN O, ZANNAD F, AARSALAND T, DICKSTEIN K, THE OPTIMAAL Trial Study Group. Early serum levels of tissue inhibitor of metalloproteinases-1 but not matrix metalloproteinase-1 are associated with cardiovascular death after complicated myocardial infarction. *JACC 2004, 1087-106 (poster)*

ZANNAD F, KETELSLEGERS JM, SCHIFFRIN EL, WILLIAMS G, GARTHWAITE S, HE W, PATNI R, PITT B. The effect of eplerenone on markers of cardiac fibrosis: insights from EPHEBUS. *JACC 2004, 1108-123*

REMME WJ, CLINE C, COHEN SOLAL A, DIETZ R, HOBBS R, KEUKELAAR K, SENDON JL, MACARIE C, MCMURRAY J, OPASICH, RAUCH B, RUZYLLO W, ZANNAD F. Inadequate perception of heart failure is associated with underuse of diagnostic and therapeutic strategies in heart failure by the primary care physician: results from SHAPE, a major european survey. *JACC* 2004, 1145-123

MANHENKE CA, STEIN O, ZANNAD F, AARSLAND T, DICKSTEIN K, THE OPTIMAAL Trial Study Group. Early elevation of C-Terminal telopeptide of type I collagen is highly correlated with 30-day mortality in patients with myocardial infarction regardless of infarct localization. *JACC* 2004, 826-3

MALKALI F, ANTUNES L, AYALEW A, MAYAP NZIETCHUENG, MENU P, LAPICQUE F, MARIE PY, LACOLLEY P, KARCHER G, ZANNAD F. L'ischémie myocardique à faible flux est associée à une importante restriction liquidienne dans l'espace interstitiel. *Arch Mal Cœur Vaiss* 2004;97(4):07-15

HANRIOT D, BELLO G, HESS K, GROSJEAN S, LATGER-CANNARD V, ROPARS A, ZANNAD F, LACOLLEY P, MERTES PM, LONGROIS D. Effets de la protéine C-réactive sur le monocyte humain ex-vivo dans la pathogénèse des maladies cardiovasculaires. *Arch Mal Cœur Vaiss* 2004;97(4):01-26

ZANNAD F, KESSLER M, GRUNFELD JP, THUILLIEZ C, LEIZOROVICZ A, LECHAT P, ROUGEMOND E, AMELLAL N. The effects of Fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. The FOSIDIAL study. *J Hypertens* 2004,22 (suppl 2): 2A.1

ZANNAD F, MEBAZZA A, COHEN SOLAL A, JUILLIERE Y, GUIZE L, ALLA F, DESNOS M, BLIN P, PAOLOZZI L, ROUGE P. Contribution of hypertension and preserved left ventricular systolic to acute heart failure : the EFICA study. *J Hypertens* 2004,22 (suppl 2): P1.388

ZANNAD F, PITT B. EPHEBUS: evidence for the cardioprotective effects of selective aldosterone blockade. *J Hypertens* 2004,22 (suppl 2): 8A.1

ANDREJAK M, ZANNAD F, LAVILLE M, DURU G, MOURAD JJ, WAEBER B. Better efficacy in hypertension management with perindopril/indapamide (PER/IND) strategy compared to sequential or step by step strategies. STRATHE study : STRAThegies of Treatment in Hypertension: Evaluation. *J Hypertens* 2004,22 (suppl 2): P3.333

BLANGY H, SADOUL N, ZANNAD F, DOUSSET B, ALLA F, RADAUCEANU A, ALIOT E. Serum markers in risk stratification of ICD recipients. *Abstract n° 101, session 18, NASPE 2004, May 19-22, San Fransisco USA*

ZANNAD F, KESSLER M, GRUNFELD JP, THUILLIEZ C, LEIZOROVICZ A, LECHAT P, ROUGEMOND E, AMELLAL N. The effects of fosinopril on cardiovascular morbidity and mortality in haemodialysis patients. The FOSIDIAL study. *Eur Heart J* 2004,25:P2830

ZANNAD F, MEBAZZA A, JUILLIERE Y, GUIZE L, COHEN-SOLAL A, ALLA F, BLIN P, PAOLOZZI L. The heterogeneity of acute heart failure. Influence of patients characteristics upon admission and history of CHF before admission on short and long-term survival: the EFICA study. *Eur Heart J* 2004,25:3757

ZANNAD F, MEBAZAA A, ALLA F, JUILLIERE Y, GUIZE L, COHEN-SOLAL A, BLIN P, PAOLOZZI L. Pre-admission and 4 week mortality in patients with acute decompensated heart failure: the EFICA study. *Eur Heart J* 2004,25:P509

ZANNAD F, MEBAZAA A, COHEN-SOLAL A, JUILLIERE Y, GUIZE L, ALLA F, BLIN P, PAOLOZZI L. Incidence of preserved left ventricular function and determinants of short-term mortality in patients with acute heart failure: the EFICA study. *Eur Heart J* 2004,25:851

KETELSLEGERS J, ZANNAD F, SCHRIFFRIN E, GARTHWAITE S, PATNI R, PITT B. The effect of eplerenone on the cytokine osteopontin in post-MI heart failure: an EPHESES substudy. *Eur Heart J* 2004,25:P2912

RAJAGOPALAN S, ZANNAD F, RADAUCEANU A, GLAZER R, CHENG J, PRESCOTT M, PETITJEAN H, PITT B. Therapeutic synergism of statins with angiotensin receptor blockade : insights from a double blind prospective randomized controlled trial. *Circulation* 2004, in press

PITT B, ZANNAD F. Effect of eplerenone on early mortality in patients with heart failure and left ventricular systolic dysfunction post-myocardial infarction (EPHESES). 1st European Society of Cardiology, Working Group on Acute Cardiac Care, October 17-20, 2004 in Rome

ZANNAD F, PILORGET V, DUBROCA I, LECLERCQ F, HABIB G, GENES N, MOUNIER-VEHIER C. Tolérance du ramipril, 10mg chez les patients à haut risque cardio-vasculaire : resultants de l'étude EDIT. *Arch Mal Cœur Vaiss* 2004,97:P120

MOURAD JJ, WAEBER B, ZANNAD F, LAVILLE M, DURU G, ANDREJAK M. Efficacité d'une plurithérapie IEC/diurétique faiblement dosée (PRETERAX) comme traitement de première intention chez les patients hypertendus de stade II. *Arch Mal Cœur Vaiss* 2004,97:P127

2005

ZANNAD F. Natriuretic peptides and heart failure. Therapeutic perspectives. *Arch Mal Coeur Vaiss* 2005,98:C233

ZANNAD F. Heart Failure: toward which management for what cost? *Arch Mal Coeur Vaiss* 2005,98:A301

ZANNAD F. RAAS blockade is there a benefit beyond blood pressure lowering? *Arch Mal Coeur Vaiss* 2005,98:S407

ZANNAD F. Ace inhibitors in coronary artery patients. Lessons from clinical trials. *Arch Mal Coeur Vaiss* 2005,98:S458

RADAUCEANU A, VIRION JM, DUCKI C, CAPIAUMONT J, LI M, ZANNAD F. Functional capacity as assessed by 6-minute walk test is strongly associated with cardiac fibrosis in patients with chronic heart failure. *JACC* 2005,45/1161-166

ANDERSON J, ZANNAD F, SOLOMON H, MUKHERJEE R, PATNI R, PITT B. Efficacy of Eplerenone in Killip Class II-III Post-AMI Patients: Results from EPHESES. *JACC* 2005,45/1147-233

REMME W, ZANNAD F, RAUCH Bernhard, McMURRAY J, COHEN-SOLAL A, KEUKELAAR K, BOCCANELLI A, LOPEZ-SENDON J, HOBBS R, MACARIE C, DIETZ R, RUZYLLO W, CLINE C. Awareness of recommended Heart Failure. Management among specialists. Do internists, Geriatricians, and Cardiologists Differ? Results of SHAPE. *JACC* 2005,45:1058-183

MASKALI F, TRAN N, NLOGA J, LAURENS MH, MARIE PY, KARCHER G, ZANNAD F. Indium-111 Oxine Labelling of Rat Bone Marrow-Derived Mesenchymal Stem Cells for In Vivo Imaging During Autologous Cell Therapy of Myocardial Infarction. *JACC* 2005,45:824-8

RADAUCEANU A, BOIVIN JM, RAY F, BERNAUD C, DABROWSKI T, ZANNAD F. Improving assessment of time-effect profile for antihypertensive drugs: a standardized method for a better estimation of the trough to peak ratio. *Fun Clin Pharmacol* 2005,19:O38

VAN VELHUISEN DJ, ASCHERMANN M, ZANNAD F, KRUM H, VINCENT J, MUKHERJEE R, PITT B. Eplerenone benefit at 30 days in high-risk subgroups in the EPHEBUS trial. *Heart Failure 2005 in press*

BELLO G, CAILOTTO F, HANRIOT D, LONGROIS D, HESS K, NZIETCHUENG R, LATGER-CANNARD V, ZANNAD F, ROPARS A. Induction de l'expression du VEGF par la CRP dans le monocyte humain. *Arch Mal Coeur Vaiss 2005,98 (4):01-14*

HANRIOT D, BELLO G, HESS K, ROPARS A, DEVAUX Y, ZANNAD F, MERTES PM, LONGROIS D, SEGUIN-DEVAUX C. Une analyse par puces à oligonucléotides révèle des effets pro- et anti-inflammatoires de la Protéine C-Réactive sur les monocytes humains. *Arch Mal Coeur Vaiss 2005,98 (4):01-16*

MASKALI F, POUSSIER S, BOUTLEY H, TRAN N, GROUBATCH F, FRANKEN P, VANHOVE C, KARCHER G, ZANNAD F, BERTRAND A. Imagerie du remodelage et de la fibrose cardiaque après occlusion coronaire chez le rat. *Arch Mal Coeur Vaiss 2005,98 (4):05-03*

ZANNAD F. Managing hypertension: a question of STRATHE. *Journal of Hypertension 2005,23(2) :105*

MOURAD JJ, WAEBER B, ZANNAD F, LAVILLE M, DURU G, ANDREJAK M. Efficacy of a first-line low-dose ACEI/DIURETIC combination therapy (PRETERAX) in stage II hypertensive patients. *Journal of Hypertension 2005,23(2) :P1.332*

DEWACHTER P, JOUAN-HUREAUX, DE TALANCE N, ZANNAD F, LONGROIS D, MERTES PM. Déficit en arginine vasopressine mis en évidence dans un modèle de choc anaphylactique chez le rat Brown Norway anesthésié sensibilisé à l'ovalbumine. *Ann. Fr Anesth. Réanim 2005 ;24 :R377 (47^e congrès national de la Société Française d'Anesthésie et de Réanimation, Paris)*

SELTON-SUTY C, BANGRATZ S, BLANGY H, DOUSSET B, NIPPERT M, ZANNAD F, BREMBILLA-PERROT B, JUILLIERE Y. Relationship between Doppler tissue imaging parameters, serum markers of myocardial fibrosis and ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. *Eur Heart J 2005,26:P1594*

REMME WJ, MCMURRAY J, LOPEZ SENDON J, COHEN-SOLAL A, ZANNAD F, BOCCANELLI S, RAUCH B, KEUKELAAR K on behalf of the SHAPE Study Group. Between-speciality differences in the management of heart failure in Europe despite evidence-based guidelines – the SHAPE survey. *Eur Heart J 2005,26:P1781*

KETELSLEGERS J, ZANNAD F, VINCENT J, MUKHERJEE R, ROUSSEAU M on behalf of EPHEBUS investigators. Effect of neurohormones, cytokines, and collagen markers on the risk of all-cause mortality: results from the EPHEBUS trial. *Eur Heart J 2005,26:2765*

2006

ZANNAD F. Quel est le traitement préventif optimal de l'insuffisance cardiaque chez l'hypertendu? *Arch Mal Coeur Vaiss 2006,99(II) :C364*

GUIZE L, ZANNAD F, MEBAZAA A, JUILLIERE Y, COHEN-SOLAL A, ALLA F. L'œdème aigu du poumon de l'hypertendu : l'étude EFICA. *Arch Mal Coeur Vaiss 2006,99 (II) : C365*

ZANNAD F. Insuffisance cardiaque aiguë : l'importance du problème. *Arch Mal Coeur Vaiss 2006,99(II) :C706*

DEWACHTER P, JOUAN-HUREAUX V, DE TALANCE N, ZANNAD F; LONGROIS D, MERTES PM. Déficit en Arginine Vasopressine mis en évidence dans un modèle de choc anaphylactique chez le rat Brown Norway sensibilisé à l'ovalbumine. *Congrès de Médecine Interne 2006 15,16 et 17 Juin – Nancy. SNFMI sous presse*

BOUTOUYRIE P, PERRET L, BOZEC E, VAN BORTEL L, JOANNIDES R, KEARNEY-SCHWARTZ A, KUNZ C, PANNIER B, PITHOIS-MERLI I, STRUIJKER-BOUDIER H, LAURENT S, SIMON T. Le contrôle qualité et la lecture centralisée améliore la reproductibilité de la mesure de l'épaisseur intima media carotidienne : l'étude CASHMERE et le réseau GAMETE. *Arch Mal Cœur Vaiss* 2005,98 :P54

BLANGY H, SADOUL N, ZANNAD F, DOUSSET B, ALLA F, RADAUCEANU A, ALIOT E. Increased collagen type I/III ratio as predictor of VT in coronary artery disease patients. *Europace* 2005 ;7(s1) :96 (432)

FELLSTROM B, ZANNAD F, SCHMIEDER R, HOLDAAS H, JARDINE A, ROSE H, WILPSHAAR W. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – baseline data from the AURORA study. 14th International Symposium on Atherosclerosis, 18-22 June 2006, Rome, July. *Atherosclerosis Supplements* 2006; 7(3):578 Abs Th-P16:387

ZANNAD F, FAY R. Blood pressure lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists. An overview of randomized controlled studies. *Journal of Hypertension* 2006, 24 (suppl 4):P1.2

ZANNAD F. A continuum of benefits with Coversyl in cardiovascular disease. *Journal of Hypertension* 2006, 24 (suppl 4):S.4.5

DELLEGROTtaglie S, ZANNAD F, GILLESPIE B, ZHANG X, FINKELSTEIN F, KISER M, EISELE G, HINDERLITER A, LEVIN N, CATTAN V, SENGSTOCK D, RAJAGOPALAN S, SARAN R. Plasma Amino-terminal propeptide of procollagen type III (PIIINP) correlates with vascular stiffness in Chronic Kidney Disease (CKD): the Renal Research Institute (RRI)-CKD Study. 2006

BLANGY H, SADOUL N, ZANNAD F, DOUSSET B, FAY R, ALIOT E. Serum markers in risk stratification in ICD recipients after MI. XVIes Journées Européennes de la Société Française de Cardiologie. *Arch Mal Cœur Vaiss* 2006,99(II) :C409

BLANGY H, SADOUL N, ZANNAD F, DOUSSET B, ALLA F, RADAUCEANU A, ALIOT E. Serum markers in risk stratification in ICD recipients. *Europace* 2004 ;6(s1) :1-203 (148-2)

GUIZE L, ZANNAD F, MEBAZAA A, JUILLIERE Y, COHEN-SOLAL A, ALLA F pour les investigateurs de l'étude EFICA. L'œdème aigu du poumon de l'hypertendu : l'étude EFICA. *Arch Mal Cœur Vaiss* 2006,99(II) :C365

LAURENT S, BOUTOUYRIE P, CHRISTIN-MAITRE S, GOMPEL A, JAILLON P, THUILLEZ C, ZANNAD F, PITHOIS-MERLI I, SIMONEAU D, SIMON T. Deleterious effects of beta-blockers on arterial stiffness and central pulse pressure in postmenopausal women : baseline findings from the CASHMERE trial. **2006, in press (poster AHA)**

2007

ZANNAD F. Understanding acute pulmonary edema in hypertensive patients. *Arch Mal Cœur Vaiss* 2007, 100 :C336

SIMON T, BOUTOUYRIE P, CHRISTINE-MAITRE S, GOMPEL A, LAURENT S, THUILLEZ C, ZANNAD F, PITHOIS-MERLI I, SIMONEAU D. La durée de la ménopause, l'âge à la ménopause et l'absence d'un THS sont associés à une augmentation de l'épaisseur et la rigidité artérielle : données d'inclusion de l'étude CASHMERE. *Arch Mal Cœur Vaiss* 2007, 100 :PC688

LAURENT S, BOUTOUYRIE P, CHRISTINE-MAITRE S, GOMPEL A, JAILLON P, THUILLEZ C, ZANNAD F, PITHOIS-MERLI I, SIMONEAU D, SIMON T. Effets délétères des betabloquants sur la rigidité artérielle et la pression pulsée centrale chez les femmes ménopausées : données d'inclusion de l'étude CASHMERE. *Arch Mal Cœur Vaiss* 2007, 100 :PC 792

ZANNAD F. Blood pressure lowering, necessary but not sufficient? *Arch Mal Cœur Vaiss* 2007, 100 :S536

ZANNAD F. Place des bloqueurs du SRAA dans la prise en charge du post-IDM. *Arch Mal Cœur Vaiss* 2007, 100 :S391

SIMON T, BOUTOUYRIE P, CHRISTIN-MAITRE S, GOMPEL A, JAILLON P, THUILLEZ C, ZANNAD F, PITHOIS-MERLI I, SIMONEAU D, LAURENT S. Deleterious effects of beta-blockers on arterial stiffness and central pulse pressure in menopausal women : baseline findings from the CASHMERE trial. *Fund Clin Pharmacol* 2007,21(supp 1):80

SIMON T, BOUTOUYRIE P, CHRISTINE-MAITRE S, GOMPEL A, JOANIDES R, KEARNEY-SCHWARTZ A, KUNTZ C, PANNIER B, PORNEL B, STRUIJKER-BOUDIER H, THUILLEZ C, VAN BORTEL L, ZANNAD F, SIMONEAU D, JAILLON P. Carotid IMT and stiffness, aortic stiffness and pulse pressure : association with hormone therapy in postmenopausal women : baseline findings from the CASHMERE trial. *Fund Clin Pharmacol* 2007,21(supp 1):88

ZANNAD F. Advantages in clinical practice of first-line combination in diabetic patients. *J Hypertens* 2007,25(supp 2):pS387

MANHENKE C, ORN S, SQUIRE I, ZANNAD F, DICKSTEIN K. The relationship between N-terminal b-type natriuretic peptide and circulating markers of cardiac remodelling in patients following complicated myocardial infarction. *Eur J Heart Fail* 2007,6:10-11

ZANNAD F, ADAMOPOULOS C, FAY R, AHMED A, FILIPPATOS G, PITT B. How early should eplerenone be initiated in acute myocardial infarction complicated by heart failure? An analysis of early vs late initiation in the EPHEBUS trial. *Eur Heart J* 2007,28(abstract suppl):52

AHMED A, ZANNAD F, YOUNG JB, WAAGSTEIN F, WHITE M, RAHIMTOOLA SH. Digoxin and reduction in early mortality in chronic heart failure: insights into the lack of late mortality reduction in the digitalis investigation group trial. *Eur Heart J* 2007,28(abstract suppl):46-47

WANG NC, KONSTAM MA, GHEORGHIAD E M, BECHHOFFER R, BURNETT JC, GRINFELD L, SWEDBERG K, UDELSON JE, COOK TH, OUYANG J, ZIMMER C, ORLANDI C, MAGGIONI AP, ZANNAD F, on behalf of the EVEREST investigators. Regional comparison of baseline characteristics in patients hospitalized with worsening heart failure and reduced ejection fraction in the EVEREST trial. *11th HFSA annual scientific meeting, J Card Fail* 2007,13(abstract suppl 6):S134 (204)

WANG NC, ZANNAD F, KONSTAM MA, BECHHOFFER R, GHEORGHIAD E M, BURNETT JC, GRINFELD L, SWEDBERG K, UDELSON JE, COOK TH, OUYANG J, ZIMMER C, ORLANDI C, MAGGIONI AP, on behalf of the EVEREST investigators. The QRS duration predicts mortality and rehospitalization in patients with worsening heart failure in the EVEREST trial. *11th HFSA annual scientific meeting, J Card Fail* 2007,13(abstract suppl 6):S142 (233)

ZANNAD F, WANG NC, KONSTAM MA, BECHHOFFER R, GHEORGHIAD E M, BURNETT JC, GRINFELD L, SWEDBERG K, UDELSON JE, COOK T, OUYANG J, ZIMMER C, ORLANDI C, MAGGIONI AP AND THE EVEREST INVESTIGATORS. Regional differences in baseline characteristics and outcomes in patients hospitalized with worsening heart failure and systolic dysfunction. *11th HFSA annual scientific meeting, J Card Fail* 2007,13(abstract suppl 6):018